Full Text View
Tabular View
No Study Results Posted
Related Studies
Effects of CX516 on Functioning in Fragile X Syndrome and Autism
This study has been completed.
Study NCT00054730   Information provided by Cortex Pharmaceuticals
First Received: February 7, 2003   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Fragile X Syndrome
Autism
Additional conditions recognized in this trial
Autistic Disorder
Syndrome
More general conditions related to this trial
Child Development Disorders, Pervasive
Chromosome Disorders
Congenital Abnormalities
Disease
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System
Mental Disorders
Mental Disorders Diagnosed in Childhood
Mental Retardation
Mental Retardation, X-Linked
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Pathologic Processes
Sex Chromosome Disorders
Interventions listed in this trial
CX516 (Ampalex®)
Sponsors listed in this trial
Cortex Pharmaceuticals
Fragile X Research Foundation of Canada


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services